Authors
Danielle Simmons, Phyllis Raynor, Don DuBose, Beverly Baliko, Lori Vick
Published in
Journal of the American Psychiatric Nurses Association. Pages 10783903261499294. Nov 11, 2026. Epub Nov 11, 2026.
Abstract
This discussion paper provides psychiatric nurses with a comprehensive, balanced review of the current evidence on the use of ketamine for treatment-resistant depression (TRD), including its mechanisms of action, clinical indications, administration, and key clinical considerations.
Recent clinical evidence on ketamine use for TRD is reviewed in this discussion paper.
Current evidence indicates that among adults with TRD receiving psychiatric care, ketamine can produce rapid, clinically meaningful antidepressant effects, with an estimated number needed to treat (NNT) of 3 within 1 day to 1 week following treatment and 9 at 4 weeks. Evidence also suggests that ketamine is noninferior to electroconvulsive therapy (ECT), a well-established and highly effective treatment for severe depression and TRD. Compared with ECT, ketamine has also been associated with fewer memory-related adverse effects and a lower overall adverse-event rate (25% vs. 32%). Together, these findings support the potential role of ketamine in psychiatric practice when accompanied by appropriate patient assessment, monitoring, and follow-up.
It is imperative that clinicians remain informed about emerging treatments for TRD and maintain open, informed dialogue with patients about its therapeutic potential.
PMID:
43016146
Bibliographic data and abstract were imported from PubMed on 12 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0